drugset / Trial / NCT03893669

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

NCT03893669

Phase 1 Completed 100 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A randomized, double-blinded, controlled, Phase I clinical trial to assess the safety, tolerability and immunogenicity of 'NBP607(trivalent inactivated cell-culture influenza vaccine)' compared to egg-based influenza vaccine in healthy adult volunteers

Timeline

Start
2012-09
Primary completion
2012-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Agrippal Vaccine 0.5 ml Intramuscular
Subject NBP607 Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.